Zim Laboratories Share News - Latest Updates, Live News & More

Latest news about Zim Laboratories

ZIM Laboratories Receives DMCC Authority Approval for Closure of Step-Down Subsidiary ZIM DMCC 9 days ago

ZIM Laboratories Limited has obtained DMCC Authority approval for closing its step-down subsidiary ZIM Laboratories Middle East DMCC, effective February 23, 2026. This follows the Board of Directors' earlier approval in August 2025 for the subsidiary closure. The company has properly disclosed this development to BSE and NSE under SEBI regulations, completing the regulatory requirements for the subsidiary's dissolution.

ZIM Laboratories Receives Credit Rating Reaffirmation from ACUITE Ratings Feb 17, 2026

ZIM Laboratories Receives GST Demand Notice of Rs. 2.19 Crore for FY 2021-22 Feb 11, 2026

ZIM Laboratories Q3FY26 Revenue Grows 12.8% to ₹1,087 Mn, PAT Turns Positive at ₹44 Mn Feb 11, 2026

ZIM Laboratories Strengthens Senior Management with Key Appointments and Categorizations Feb 02, 2026

More news about Zim Laboratories

22Jan 26

ZIM Laboratories Publishes EGM Notice for February 16, 2026 Meeting

ZIM Laboratories Limited has published newspaper advertisements announcing its Extraordinary General Meeting scheduled for February 16, 2026, at 11:30 AM IST via video conferencing. The company published notices in The Financial Express, Indian Express, and Lokatta newspapers on January 22, 2026, in compliance with SEBI regulations. The EGM notice will be accessible through multiple digital platforms including company website and stock exchange portals.

21Jan 26

Zim Laboratories Board Approves Share Issuance Plan Worth ₹35 Crores to Florintree Trinex LLP

Zim Laboratories Limited's board has approved issuing up to 47,64,497 shares at ₹73.46 each to Florintree Trinex LLP, representing approximately ₹35 crores in value. The company has scheduled a special shareholder meeting for February 16, 2026, to obtain formal approval for this significant capital raising initiative. This structured approach demonstrates proper corporate governance with board approval preceding shareholder consent.

17Nov 25

ZIM Laboratories Reports Sequential Recovery in Q2 FY26 Amid EU-GMP Challenges

Zim Laboratories Limited showed sequential recovery in Q2 FY26 despite EU-GMP compliance challenges. Operating income increased by 23.60% to INR 887.00 million, with EBITDA margin improving to 8.80%. The pharmaceutical segment grew 30.70% QoQ, while the nutraceutical segment declined. The company aims to complete EU-GMP audit by March 2026 and resume supplies by Q1 or Q2 FY27. Business continuity measures include reviewing emerging market orders and initiating site transfers for key products. FY26 revenues are expected to align with FY25 levels, with a strong Q3 order book and anticipated nutraceutical segment recovery in H2 FY26.

13Nov 25

ZIM Laboratories Reports Q2 FY2026 Loss Amid Challenging Market Conditions

Zim Laboratories announced its Q2 and H1 FY2026 results, reporting a consolidated net loss of Rs 42.46 lakhs for Q2, down from a profit of Rs 238.14 lakhs in Q2 FY2025. Total operating income for Q2 FY2026 decreased by 3.7% year-on-year to Rs 8,871.13 lakhs. The pharma segment grew 11.9% year-on-year, contributing 83% to total revenue. Export business declined 4% year-on-year but maintained 82% of total revenue. The company entered an agreement to sell unused MIDC land and acquired new land for potential expansion. Despite challenges, Zim Laboratories continues to focus on strategic growth, innovation, and R&D investment.

13Oct 25

ZIM Laboratories Seeks Shareholder Approval for Re-appointment of Two Whole-time Directors

Zim Laboratories Limited has announced a postal ballot for the re-appointment of two Whole-time Directors, Mr. Niraj Dhadiwal and Mr. Prakash Sapkal, for a two-year term from October 1, 2025, to September 30, 2027. The proposed remuneration package includes a fixed salary up to Rs. 1.50 crores and performance-linked incentives up to Rs. 50 lakhs. E-voting will be conducted from October 15 to November 13, 2025, with results announced by November 15, 2025. Both directors have over 30 years of experience in the pharmaceutical industry and have been instrumental in the company's growth. This move aims to ensure leadership continuity as Zim Laboratories expands into regulated markets like the EU.

19Sept 25

ZIM Laboratories Reappoints Two Whole-Time Directors for Extended Terms

Zim Laboratories Limited has reappointed Mr. Niraj Dhadiwal as Director - Business Development and Mr. Prakash Sapkal as Whole-Time Director for an additional two-year term starting October 1, 2025. The decision was made by the Board of Directors on September 19, 2025, following recommendations from the Nomination and Remuneration Committee. Both reappointments are subject to shareholder approval. Mr. Dhadiwal, with nearly 30 years of experience at Zim Laboratories, oversees business development and marketing functions. Mr. Sapkal, with 26 years at the company, has been crucial in operational roles. Both executives are not debarred from holding directorial positions and are not related to other board members.

07Aug 25

ZIM Laboratories Reports Q1 FY26 Loss, Appoints New Internal Auditor and Restructures Subsidiaries

Zim Laboratories Limited reported a consolidated net loss of Rs 187.49 lakhs for Q1 FY26, compared to a profit of Rs 89.83 lakhs in Q1 FY25. Revenue from operations decreased by 12.30% to Rs 7,175.61 lakhs. EBITDA fell 36.70% to Rs 57 lakhs, with the margin decreasing to 7.90%. The company's business mix showed 78% revenue from Pharma and 22% from Nutra segments. Strategic decisions include appointing a new internal auditor, investing in a GCC subsidiary, and closing a UAE subsidiary. R&D spending remained strong at 11% of operating income, with progress in new product development for the EU market.

21Jul 25

Zim Laboratories Secures First Australian Approval for Migraine Treatment

Zim Laboratories' subsidiary, Zimtas Pty Ltd, has received Marketing Authorization from the Therapeutic Goods Administration (TGA) in Australia for Rizatriptan Benzoate Orally Disintegrating Films. This approval marks the company's entry into the Australian pharmaceutical market and validates its oral thin film platform technology. The product, designed for acute migraine treatment, offers advantages such as rapid onset and convenience for patients. This milestone is expected to facilitate commercial launch in Australia, potential expansion in the Asia-Pacific region, and further establish Zim's innovative drug delivery technologies globally.

19Jun 25

Zim Laboratories Invests Rs 2.70 Crore in Latvian Subsidiary SIA ZIM

Zim Laboratories has invested Rs 2.70 crore (approximately €300,000) in its Latvian subsidiary, SIA ZIM. This strategic move aims to strengthen the company's presence in the European market. Latvia, being an EU member, provides a strategic location for accessing the broader European pharmaceutical landscape. The investment is expected to support growth initiatives and enhance the company's capabilities in the region.

20May 25

ZIM Laboratories Q4 Results: EBITDA Margin Improves Despite Revenue Dip

ZIM Laboratories' Q4 financial results show a 7.63% year-over-year revenue decline to ₹1.09 billion. Despite this, the company improved its EBITDA margin to 13.42% from 13.28%. EBITDA slightly decreased to ₹146.00 million, while net profit fell significantly by 39.68% to ₹48.80 million compared to the same quarter last year. The results indicate challenges in revenue growth but demonstrate the company's focus on operational efficiency.

09Apr 25

ZIM Laboratories Expands into GCC Market with Globalpharma Partnership

ZIM Laboratories Limited, an Indian pharmaceutical company, has formed a strategic partnership with UAE-based Globalpharma Co. (L.L.C.) to introduce innovative oral thin film products in the Gulf Cooperation Council (GCC) region. The collaboration involves licensing ZIM's ThinOral® technology, registering 10 OTF-based products, and establishing a supply chain for localized manufacturing. This partnership aims to expand ZIM's presence in the Middle Eastern market while leveraging Globalpharma's regional footprint.